Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Insight Molecular Diagnostics (IMDX) Assets Average: 2020-2025

Historic Assets Average for Insight Molecular Diagnostics (IMDX) over the last 4 years, with Sep 2025 value amounting to $47.2 million.

  • Insight Molecular Diagnostics' Assets Average fell 34.83% to $47.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $47.2 million, marking a year-over-year decrease of 34.83%. This contributed to the annual value of $55.0 million for FY2024, which is 37.15% down from last year.
  • According to the latest figures from Q3 2025, Insight Molecular Diagnostics' Assets Average is $47.2 million, which was down 14.81% from $55.4 million recorded in Q2 2025.
  • In the past 5 years, Insight Molecular Diagnostics' Assets Average registered a high of $172.9 million during Q3 2021, and its lowest value of $47.2 million during Q3 2025.
  • For the 3-year period, Insight Molecular Diagnostics' Assets Average averaged around $64.9 million, with its median value being $72.5 million (2024).
  • In the last 5 years, Insight Molecular Diagnostics' Assets Average surged by 189.68% in 2021 and then plummeted by 39.22% in 2023.
  • Insight Molecular Diagnostics' Assets Average (Quarterly) stood at $164.0 million in 2021, then declined by 21.49% to $128.7 million in 2022, then tumbled by 39.22% to $78.2 million in 2023, then plummeted by 32.71% to $52.6 million in 2024, then crashed by 34.83% to $47.2 million in 2025.
  • Its last three reported values are $47.2 million in Q3 2025, $55.4 million for Q2 2025, and $47.7 million during Q1 2025.